Congenital Heart Disease Skin Punch Biopsy Sample Collection

Overview

About this study

The purpose of this study is to Generate autologous iPSC in a manner compliant with requirements for future clinical use, and Reduce manufacturing time when patients are identified as eligible to receive product under separate interventional treatment protocol.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 and older.

  • Congenital heart disease.

  • Likely to qualify for an active clinical trial under IND 28611 in the future.

Exclusion Criteria: 

  • Previous cardiac transplantation.

  • Unable or unwilling to consent.

  • HIV diagnosis.

  • Hepatitis diagnosis.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/4/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Rebecca Ameduri, M.D.

Closed for enrollment

Contact information:

Hypoplastic Left Heart Syndrome Research Group

hlhs@mayo.edu

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions